UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant $\, x \,$

Filed by a Party other than the Registrant o

Check the appropriate box:

- o Preliminary Proxy Statement
- o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- o Definitive Proxy Statement
- x Definitive Additional Materials
- o Soliciting Material Pursuant to §240.14a-12

ImmunoGen, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.

0

- o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:
 - (5) Total fee paid:

o Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

*** Exercise Your *Right* to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on November 16, 2010.

IMMUNOGEN, INC.

IMMUNOGEN, INC. 830 WINTER STREET WALTHAM, MA 02451

Meeting Information

Meeting Type: Annual For holders as of: September 21, 2010 Date: November 16, 2010 Time: 11:00 a.m., EST Location: ImmunoGen, Inc. Company Offices 830 Winter Street Waltham, MA 02451

You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

– Before You Vote —

How to Access the Proxy Materials

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before November 2, 2010 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

M26969-P01376

Voting Items

The Board of Directors recommends that you vote FOR the following:

2. Election of Directors

Nominees:

- 01)
 Mitchel Sayare, Ph.D.
 06)
 Stephen C. McCluski

 02)
 David W. Carter
 07)
 Richard J. Wallace

 03)
 Mark Staletsky
 08)
 Daniel M. Junius

 04)
 Joseph J. Villatranca, Ph.D.
 09)
 Howard H. Pien

 05)
 Nicole Onetto, MD
 09
 Howard H. Pien

The Board of Directors recommends you vote FOR the following proposals:

- 1. To fix the number of members of the Board of Directors at nine (9)
- To approve an amendment to the 2006 Employee, Director and Consultant Equity Incentive Plan to increase the number of shares
 of common stock authorized for issuance thereunder by 4,000,000
- To ratify the appointment of Ernst & Young LLP as Immuno/Gen's independent registered public accounting firm for the fiscal year ending June 30, 2011

In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournments thereof.

M26971-P01376